Insider trade

CFO received an award of 84K ROIV derivative securities

Traded Apr 20, 2026 · Filed Apr 23, 2026

Roivant SciencesROIV

84K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Apr 20, 2026
Reporting period: Not applicable
Filed with the SEC: Apr 23, 2026

CFOGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001635088-26-000043
Filed / recorded

Apr 23, 2026, 2:26 AM UTC

Added to OQRO

Oct 6, 2026, 8:46 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Roivant Sciences Ltd.

Issuer CIK

1635088

Ticker

ROIV

Reporting person

Richard Pulik

Relationship

Officer

Officer title

CFO

Security

Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Apr 20, 2026

Transaction code

A

Shares / units

84,026

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

84,026

Ownership form

Direct

Amendment

No

Footnotes from the filing

Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2026. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in thirty-six (36) successive equal monthly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through the applicable vesting date.